[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Ixico Plc LSE:IXI London Ordinary Share GB00BFXR4C20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 74.00 72.00 75.00 75.00 73.50 75.00 42,835 16:35:04
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 9.5 0.9 2.0 36.6 35

IXICO plc Contract win for new stroke study

28/04/2021 7:00am

UK Regulatory (RNS & others)


Ixico (LSE:IXI)
Historical Stock Chart


From Mar 2021 to Sep 2021

Click Here for more Ixico Charts.

TIDMIXI

RNS Number : 7921W

IXICO plc

28 April 2021

IXICO plc

("IXICO" or the "Company")

Contract win for new stroke study

New therapeutic area, broadening IXICO's neurological footprint

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience , announces that it has executed a contract to provide neuroimaging services for a new clinical trial for acute ischemic stroke with its largest pharma client.

The contract win reflects a further broadening of IXICO's neurological footprint into a new therapeutic area with this client and demonstrates that the Company continues to build momentum in its growth strategy of further diversification into new therapeutic areas. Ischemic stroke is caused by a blockage cutting off the blood supply to the brain. This is the most common form of stroke and accounts for approximately 85% of cases. The new Phase II acute ischemic stroke trial, will be conducted across 50 sites in North America and Europe and is worth in excess of US$0.5m over 35 months.

Lammert Albers, Chief Commercial Officer of IXICO, commented: "We are delighted to be awarded this new study by our existing pharma client. Having singularly focused on neurological disorders since our inception in 2004, IXICO has a long and established history of delivering advanced neuroimaging solutions to the biopharmaceutical sponsors. This new contract demonstrates our continually expanding footprint and deepening expertise within IXICO's proven specialist domain. "

For further information please contact:

 
 IXICO plc                                      +44 (0)20 3763 7498 
 Giulio Cerroni, Chief Executive Officer 
  Grant Nash, Chief Financial Officer 
 
 Cenkos Securities PLC (Nominated adviser 
  and sole broker)                              +44 (0)20 7397 8900 
 Giles Balleny / Max Gould (Corporate 
  Finance) 
 Michael F Johnson / Russell Kerr 
  (Sales) 
 
 Walbrook PR Ltd                                +44 (0)20 7933 8780 
 Paul McManus / Lianne Cawthorne               IXICO@walbrookpr.com 
  / 
 Alice Woodings 
 
 

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.

   More information is available on www.IXICO.com   and follow us on Twitter @IxicoNews 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

CNTSESESWEFSEDL

(END) Dow Jones Newswires

April 28, 2021 02:00 ET (06:00 GMT)

1 Year Ixico Chart

1 Year Ixico Chart

1 Month Ixico Chart

1 Month Ixico Chart
ADVFN Advertorial
Your Recent History
LSE
IXI
Ixico
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210921 05:28:20